Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164226 | 0.86 | MEN1 (0.32) | — | |
| SCHEMBL862783 | 0.82 | CYP1A2 (0.42) | CYP2A6CYP1A2ALDH1A1AHRPLAU | |
| SCHEMBL16442543 | 0.82 | ALDH1A1 (0.44) | CYP2A6CYP1A2ALDH1A1AHRPSMB8 | |
| SCHEMBL15497403 | 0.82 | CYP1A2 (0.50) | CYP2A6CYP1A2ALDH1A1AHRPLAU | |
| SCHEMBL142551 | 0.82 | CYP1A2 (0.55) | CYP2A6CYP1A2ALDH1A1AHR | |
| SCHEMBL29364650 | 0.82 | CYP1A2 (0.55) | CYP2A6CYP1A2ALDH1A1AHR | |
| Hydrogen Sulfide SCHEMBL28590036 | 0.80 | CYP1A2 (0.52) | CYP2A6CYP1A2ALDH1A1AHR | |
| SCHEMBL12925898 | 0.78 | GPR3 (0.46) | ALDH1A1 | |
| SCHEMBL4921490 | 0.76 | ESR2 (0.33) | — | |
| SCHEMBL4911271 | 0.76 | MEN1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061755-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | disclosed |
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-12 | — | — | US | disclosed |
| WO-2008109840-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | TFRC, SLC40A1, FECH | CYP2A6 763/4885CYP1A2 313/4885ALDH1A1 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.